ShapiroSZ: Clinical development of candidate HIV vaccines: Different problems for different vaccines. AIDS Res Hum Retroviruses, 2014; 30(4):325–329.
2.
HansenSG, et al.: Immune clearance of highly pathogenic SIV infection. Nature, 2013; 502(7469):100–104.
3.
HansenSG, et al.: Cytomegalovirus vectors violate CD8+ T cell epitope recognition paradigms. Science, 2013; 40(6135):1237874.
4.
Rerks-NgarmS, et al.: Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med, 2009; 361(23):2209–2220.
5.
McElrathMJ, et al.: HIV-1 vaccine-induced immunity in the test-of-concept Step Study: A case-cohort analysis. Lancet, 2008; 372(9653):1894–1905.
6.
HammerSM, et al.: Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine. N Engl J Med, 2013.
7.
AlizonS, et al.: Phylogenetic approach reveals that virus genotype largely determines HIV set-point viral load. PLoS Path, 2010; 6(9):e1001123.
8.
KeeleBF, et al.: Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci USA, 2008; 105(21):7552–7557.
9.
HaynesBF, et al.: Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med, 2012; 366(14):1275–1286.
10.
YangH, et al.: Antiviral inhibitory capacity of CD8+ T cells predicts the rate of CD4+ T-cell decline in HIV-1 infection. J Infect Dis, 2012; 206(4):552–561.
11.
BorthwickN, et al.: Vaccine-elicited human T cells recognizing conserved protein regions inhibit HIV-1. Mol Ther: J Am Soc Gene Ther, 2014; 22(2):464–475.
